Skip to Content

Marplan (isocarboxazid) Disease Interactions

There are 26 disease interactions with Marplan (isocarboxazid):

Major

Maoi Antidepressants (Includes Marplan) ↔ Blood Pressure

Severe Potential Hazard, High plausibility

Applies to: Cerebral Vascular Disorder, Cardiovascular Disease, Hypotension

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with cerebrovascular or cardiovascular disease, including hypertension and congestive heart failure. Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases. MAOI antidepressants are also commonly associated with dose-related orthostatic hypotension, which occurs most frequently in patients with preexisting hypertension but may be minimized with slow, gradual titration. Blood pressure should be monitored closely in all patients who receive MAOI therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).

References

  1. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  2. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
  3. Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8
View all 12 references
Major

Maoi Antidepressants (Includes Marplan) ↔ Carcinoid Syndrome

Severe Potential Hazard, High plausibility

Applies to: Carcinoid Syndrome

The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with carcinoid syndrome. Nonspecific MAOIs inhibit the breakdown of pressor amines, including serotonin, and may exacerbate symptoms of the syndrome.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
Major

Maoi Antidepressants (Includes Marplan) ↔ Headaches

Severe Potential Hazard, High plausibility

Applies to: Headache

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with a history of headaches. Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases. Since headache may often be the first symptom of a hypertensive reaction during MAOI therapy, use of these agents is not recommended in patients who experience frequent or severe headaches. MAOIs should be withdrawn promptly if headaches develop during treatment.

References

  1. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  2. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
  3. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
View all 11 references
Major

Maoi Antidepressants (Includes Marplan) ↔ Hyperthyroidism

Severe Potential Hazard, High plausibility

Applies to: Hyperthyroidism

Nonspecific monoamine oxidase inhibitors (MAOIs) inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases. Therapy with nonspecific MAOIs should be administered cautiously in patients with hyperthyroidism, since these patients have an increased sensitivity to pressor amines. Blood pressure should be monitored closely during therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).

References

  1. Fallon B, Foote B, Walsh BT, Roose SP "'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors." J Clin Psychiatry 49 (1988): 163-5
  2. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  3. Evans DL, Davidson J, Raft D "Early and late side effects of phenelzine." J Clin Psychopharmacol 2 (1982): 208-10
View all 11 references
Major

Maoi Antidepressants (Includes Marplan) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with abnormal liver function tests or a history of liver disease. A low incidence of altered liver function or hepatocellular jaundice has been reported in association with the use of MAOI antidepressants. Periodic monitoring of liver function tests is recommended during prolonged and/or high-dose therapy.

References

  1. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  2. Bonkovsky HL, Blanchette PL, Schned AR "Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material." Am J Med 80 (1986): 689-92
  3. Gomezgil E, Salmeron JM, Mas A "Phenelzine-induced fulminant hepatic failure." Ann Intern Med 124 (1996): 692-3
View all 7 references
Major

Maoi Antidepressants (Includes Marplan) ↔ Pheochromocytoma

Severe Potential Hazard, High plausibility

Applies to: Pheochromocytoma

The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas, that secrete pressor substances. Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises. Intracranial hemorrhage and death have resulted in some cases.

References

  1. Linet LS "Mysterious MAOI hypertensive episodes." J Clin Psychiatry 47 (1986): 563-5
  2. Keck PE Jr, Vuckovic A, Pope HG Jr, Nierenberg AA, Gribble GW, White K "Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment." J Clin Psychopharmacol 9 (1989): 203-6
  3. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P "Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study." J Clin Psychopharmacol 4 (1984): 270-8
View all 10 references
Major

Maoi Antidepressants (Includes Marplan) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with severe renal dysfunction. These drugs may accumulate in plasma when renal function is impaired.

References

  1. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  2. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  3. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
Major

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Alcohol

Severe Potential Hazard, Moderate plausibility

Applies to: Alcoholism, Acute Alcohol Intoxication

The use of monoamine oxidase inhibitors with alcohol or any other CNS depressants is contraindicated.

Major

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Bipolar Disorder, Depression, Psychosis

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Families and caregivers should be advised of the need for close observation and communication with the treating physician. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Major

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Hypertension/Cvd

Severe Potential Hazard, Moderate plausibility

Applies to: Hypertension, Cardiovascular Disease, Cerebral Vascular Disorder, Congestive Heart Failure

The use of most monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with diagnosed cardiovascular disease, hypertension, or confirmed or suspected cerebrovascular disorders. These drugs can cause hypertensive crises, which sometimes can be fatal, and are characterized by occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia. Intracranial bleeding has been reported in some cases in association with the increase in blood pressure.

Normotensive patients receiving therapy with MAOIs need to have monitored their blood pressure frequently to detect any evidence of pressor response and treatment should be discontinued immediately if blood pressure increases or the patient reports symptoms such a headaches or palpitations. Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger an hypertensive crisis.

Major

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of monoamine oxidase inhibitors is contraindicated in patients with a history of liver disease or in those with abnormal liver function tests.

Major

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Pheochromocytoma

Severe Potential Hazard, Moderate plausibility

Applies to: Pheochromocytoma

The use of most monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with pheochromocytoma, as such tumors secrete pressor substances whose metabolism may be inhibited by these drugs.

Major

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Severe Renal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of some monoamine oxidase inhibitors such as isocarboxazid and phenelzine, is contraindicated in patients with severe renal impairment.

Moderate

Isocarboxazid (Includes Marplan) ↔ Hepatotoxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

There has been a low incidence of altered liver function and jaundice in patients receiving isocarboxazid. This drug should be used with caution in patients with any history of liver disease. Periodic liver chemistry tests should be performed during therapy and the use of the drug should be discontinued at the fist sign of hepatic dysfunction or jaundice.

Moderate

Isocarboxazid (Includes Marplan) ↔ Hyperthyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperthyroidism

Isocarboxazid should be used with caution in hyperthyroid patients because of their increased sensitivity to pressor amines.

Moderate

Maoi Antidepressants (Includes Marplan) ↔ Hypoglycemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

There is conflicting evidence regarding whether monoamine oxidase inhibitors (MAOIs) affect glucose metabolism or potentiate oral hypoglycemic agents. Therapy with MAOIs should be administered cautiously in patients with diabetes.

References

  1. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  2. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
Moderate

Maoi Antidepressants (Includes Marplan) ↔ Parkinsonism

Moderate Potential Hazard, Moderate plausibility

Applies to: Parkinsonism

Nonspecific monoamine oxidase inhibitors (MAOIs) may increase the frequency and severity of signs and symptoms associated with parkinsonian syndrome. Therapy with nonspecific MAOIs should be administered cautiously in patients with this disorder.

References

  1. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  2. Teusink JP, Alexopoulos GS, Shamoian CA "Parkinsonian side effects induced by a monoamine oxidase inhibitor." Am J Psychiatry 141 (1984): 118-9
  3. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
View all 5 references
Moderate

Maoi Antidepressants (Includes Marplan) ↔ Schizophrenia/Bipolar

Moderate Potential Hazard, Moderate plausibility

Applies to: Schizophrenia, Bipolar Disorder, Mania

Monoamine oxidase inhibitor (MAOI) antidepressants may cause excessive stimulation in hyperactive or schizophrenic patients. Symptoms of psychosis may be aggravated in schizophrenia, particularly that with paranoid symptomatology. Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania. Therapy with MAOI antidepressants should be administered cautiously in patients with hyperactive or hyperexcitable personalities, schizophrenia or bipolar disorder.

References

  1. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
  3. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
Moderate

Maoi Antidepressants (Includes Marplan) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Monoamine oxidase inhibitor (MAOI) antidepressants may have variable effects on seizure threshold. Decreased seizure frequency as well as increased frequency have been reported. Therapy with MAOI antidepressants should be administered cautiously in patients with a history of seizures.

References

  1. "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
  3. Waghray SN, Francis K "Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics." J R Soc Med 77 (1984): 346
View all 5 references
Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Angina

Moderate Potential Hazard, Moderate plausibility

Applies to: Angina Pectoris, Myocardial Infarction

Monoamine oxidase inhibitors may have the capacity to suppress anginal pain that would otherwise serve as a warning of myocardial ischemia. Caution is advised in patients with a history of angina or risk of myocardial infarction.

Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Bipolar Disorder Screening

Moderate Potential Hazard, Moderate plausibility

Applies to: Bipolar Disorder, Depression

A major depressive episode can be the initial presentation of bipolar disorder. Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a monoamine oxidase inhibitor (MAOI). This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that MAOIs antidepressants are not approved for use in treating bipolar depression.

Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Monoamine oxidase inhibitors can increase the sensitivity to insulin, and have contributed to hypoglycemic episodes in patients with diabetes. Caution should be used when prescribing in diabetic patients.

Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Hypotension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypotension

Hypotension has been observed during therapy with monoamine oxidase inhibitors. These drugs should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.

Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Renal Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Monoamine oxidase inhibitors should be used with caution in patients with renal impairment as there is a possibility of cumulative effects in such patients. Dose selection should be cautious, usually starting at the low end of the dosing range.

Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Schizophrenia

Moderate Potential Hazard, Moderate plausibility

Applies to: Schizophrenia, Mania

Some monoamine oxidase inhibitors such as isocarboxazid and phenelzine, should be used cautiously in hyperactive and agitated patients, as well as schizophrenic patients, as these may cause excessive stimulation. Additionally, activation of mania/hypomania has been reported in a small portion of patients with major affective disorders.

Moderate

Monoamine Oxidase Inhibitors (Includes Marplan) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Monoamine oxidase inhibitors have shown a variable effect on the convulsive threshold. Caution should be used when treating patients with epilepsy.

Marplan (isocarboxazid) drug Interactions

There are 991 drug interactions with Marplan (isocarboxazid)

Marplan (isocarboxazid) alcohol/food Interactions

There are 2 alcohol/food interactions with Marplan (isocarboxazid)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide